Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Gregory Y. H. Lip
This session was co-chaired by Prof GYH Lip (Birmingham, UK) and Prof D Milicic (Zagreb, Croatia) and dealt with areas which were not necessarily covered by guidelines, on the use of anticoagulation in difficult patient populations. FWA. Verheught (the Netherlands) provided a discussion on the use of anticoagulation during pregnancy and the per-partum period. Guidelines were mostly informed by cohort studies with lack of data from randomized trials. Concerns with warfarin include those pertaining to the fetus, but overall such pregnancies have a high risk of complications. I. Porto provided an excellent and highly detailed overview of anticoagulation in patients undergoing device implantation or ablation. A very important message is that a bridging strategy is associated with a high risk of thromboembolism and bleeding. Bridging practice differs between North America and Europe . During device implantation (or even ablation) there is increasing tendency for the procedure to be done whilst the patient is still anticoagulated with warfarin. New oral anticoagulants offer some opportunities, but management needs to consider important aspects such as bleeding risk and renal function . A high HAS-BLED score has been shown to be predictive of bleeding events in patients (both AF and non-AF) undergoing bridging . D. Gulba (Germany) gave a presentation on anticoagulation in patients undergoing non-cardiac surgery. He proposed the use of the CHA2DS2-VASc score to assess thromboembolic risk when anticoagulation was subtherapeutic, even in patients with valve disease, on the assumption that the risk was a linear one following cessation of anticoagulation, or when anticoagulation was subtherapeutic. The CHA2DS2-VASc score is not validated for this purpose. F. Andreotti (Italy) gave an overview on the use of parenteral and oral anticoagulation in chronic kidney disease, which is a pretty fragile population. Such patients can be at high risk of thromboembolism and death, but are also at high risk of bleeding . In patients with atrial fibrillation, a management proposal balancing stroke and bleeding risk has been proposed .
REFERENCES 1. Pisters R and Lip GYH. Chest 2012 2. Pengo V et al. Thrombosis & Haemostasis 2011 3. Omran H et al. Thrombosis & Haemostasis 2012 4. Olesen J et al. New England Journal of Medicine 2012 5. Marinigh R et al. Journal of the American College of Cardiology 2011
Anticoagulants in special populations
© 2017 European Society of Cardiology. All rights reserved